Sector News

Lundbeck to buy Parkinson's drug developer in potential $1.1 billion deal

March 19, 2018
Life sciences

Lundbeck agreed to buy Prexton Therapeutics, a specialist in treatments for brain disorders, in a deal potentially worth $1.1 billion, the Danish drugmaker said on Friday.

Prexton has drug candidate foliglurax in phase II testing for treatment of Parkinson’s disease, with first data expected to be available in the first half of 2019.

Lundbeck, which develops and distributes drugs for neurological and psychological diseases, said it would pay 100 million euros ($123 million) up front for Prexton and make up to 805 million euros in development, regulatory and sales milestones payments.

Prexton was founded in 2012 by Francois Conquet and M Ventures, the corporate venture arm of Merck KGaA. M Ventures had still been one of Prexton’s largest shareholders, a Merck KGaA spokesman said.

Lundbeck said the deal would have no impact on its financial guidance for 2018.

“Parkinson is one of our focus areas, so this fits perfect into our strategy of buying early-stage drugs,” Lundbeck interim Chief Executive Anders Gotzsche told Reuters.

More than half of the 805 million euros in potential payments s connected to sales milestones, Lundbeck said.

“Several drugs are available on the market, but there is still unmet demand,” Gotzsche said.

Gotzsche, who stepped in as CEO after industry veteran Kare Schultz was hired by Teva in September, said Lundbeck aimed to add another one or two drugs in clinical testing phase to its portfolio this year.

($1 = 0.8112 euros)

By Teis Jensen and Jacob Gronholt-Pedersen

Source: Reuters

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend